Cairo – Mubasher: Sabaa Pharmaceutical said it expects revenues of nearly EGP 4 million from selling 2,500 units of SoviHep Hepatitis C Drug.

The revenues are expected to be reflected at the financial statements of the financial period that will end on December 2015.

Meanwhile, the company seeks to produce 50,000 units of SoviHep through the first quarter of 2016.

The drug firm reported net profits of EGP 1.6 million for the first nine months of 2015, compared with EGP 1.7 million a year earlier.